Drug
Inebilizumab
Inebilizumab: highest development phase Post-Market, developed by Amgen, Hansoh Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen, Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Inebilizumab NCT06212245 | Post-Market | Neuromyelitis Optica Spectrum Disorders |
| Inebilizumab NCT07598825 | Phase 3 | Autoimmune Hepatitis |
Latest
No recent events.
Follow Inebilizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.